AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Calix, you need to believe its shift to a software centric, AI enabled broadband platform can deepen recurring revenue while holding up margins in a competitive market. The SmartMDU news supports the near term catalyst of broader Calix One adoption by showing real world MDU wins, but does not materially change the key risk that AI and platform upgrades may be adopted more slowly than expected.
Among recent developments, the February 2026 launch of Calix One as an AI native, multi layer platform is most relevant here. SmartMDU’s traction with Blue Stream Fiber, XMission, Aervivo and others plugs directly into Calix One, tying this MDU momentum to the broader catalyst that platform adoption and AI agents could drive higher quality software and services revenue over time.
But while MDU wins can look reassuring, investors should still be aware that...
Read the full narrative on Calix (it's free!)
Calix’s narrative projects $1.3 billion revenue and $195.4 million earnings by 2028.
Uncover how Calix's forecasts yield a $75.00 fair value, a 47% upside to its current price.
While consensus sees strong upside, the most pessimistic analysts assume only about 12 percent annual revenue growth and earnings of roughly US$141.0 million by 2029, so this SmartMDU news could prove more important than their cautious AI and margin assumptions currently suggest.
Explore 5 other fair value estimates on Calix - why the stock might be worth over 2x more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com